About this trial
The ureteral access sheath (UAS) is an ancillary device widely used by urologists to facilitate fast, repeatable, and safe access to ureters and collecting systems; improve visibility; reduce the risk of infection by reducing intrarenal pressure; and protect ureters and scopes when extracting multiple stones during surgery.
Insertion of ureteric access sheath may be difficult due to tight ureter, so sometimes preoperative stenting might be needed. Silodosin is an α1A adrenoceptor with high affinity and selectivity for the ureteric muscle, which may reduce ureteral spasm.
Oral a1-blockers can reduce intraureteral pressure, and may reduce maximal ureteral access sheath insertion force.¹ Preoperative silodosin protects against significant ureteral injury related to UAS insertion during fURS and decreases postoperative pain level. Silodosin premedication might be an effective and safe technique to replace prestenting.²
Eligibility criteria
Qualifiers
All patients with renal stones who will undergo flexible ureteroscopy and planned for using ureteral access sheath
Disqualifiers
Paediatric age group (less than 18 year)
Trial design
Treatments tested in this trial
- Ureteral access sheath placement during flexible ureteroscope for renal stones
Treatment groups
Sponsors and collaborators
Al-Azhar University
Lead sponsor
Benha University
Collaborator
Alexandria University
Collaborator
Cairo University
Collaborator
Menoufia University
Collaborator
Tanta University
Collaborator